Cardiovascular disease (CVD) remains the leading cause of death worldwide, accounting for nearly 18 million deaths annually, according to the World Health Organization. In this context, alternative and non-invasive therapies such as Enhanced External Counter-pulsation (EECP) have emerged as promising tools to improve patient outcomes—particularly for those with chronic angina, heart failure, and poor peripheral circulation. While EECP has been approved in several countries, including the United States, its adoption is still growing globally. This blog aims to explore EECP from multiple dimensions: its clinical science, global research footprint, credibility in evidence-based medicine, and its potential to bring large-scale benefits...